Gencurix (https://www.gencurix.com/eng/index.php) announced clinical results of 
its prognostic test for breast cancer patients at the Global Breast Cancer 
Conference 2023. The study, 'Long-term prognostic value of GenesWellBCT score 
in Asian women with hormone receptor-positive/HER2- early breast cancer, 
involved 366 Korean and Japanese patients and was conducted by Sagara Hospital 
and Asan Medical Center. GenesWellBCT test was used for breast cancer 
prognosis. The low-risk group showed significantly higher survival rates over 
15 years after surgery than the high-risk group, demonstrating the clinical 
utility of GenesWellBCT.

Hormone receptor-positive/HER2- breast cancer, which accounts for majority of 
early breast cancer cases, has a relatively favorable prognosis compared to 
other cancer subtypes. However, there is still a risk of recurrence even after 
ten years from surgery. Accurately predicting the risk of recurrence is crucial 
for determining individual treatment plans for patients.

Traditional breast cancer prognosis tests provide prediction information for 
patient recurrence up to 10years after surgery, but it is still unclear whether 
they can accurately predict recurrence beyond 10-years.

The study, conducted on the patients at Asan Medical Center and Sagara 
Hospital, evaluated long-term prognostic performance of GenesWellBCT. The 
results showed probability of metastasis to other organs for 15-years after 
surgery was 6.4% for low-risk group and 36.7% for high-risk group as determined 
by GenesWellBCT. Significant differences in survival rates between risk groups 
were confirmed in both Korean and Japanese patient groups.

In particular, when early recurrence within 5-years after surgery and late 
recurrence between 5 and 15-years after surgery were analyzed separately, 
GenesWellBCT was able to predict both types of recurrence significantly.

Moreover, this achievement is significant given existing western breast cancer 
diagnostic products have long struggled with accuracy issues for patients under 
50-years old. GenesWellBCT has also shown to be effective regardless of age.

GenesWellBCT provides significant information on recurrence for up to 15-years, 
surpassing the 10-year predictions provided by existing tests. The study also 
highlights the significant differences between GenesWellBCT and others, which 
can only predict up to 10 years.

GenesWellBCT is the first breast cancer prognosis diagnostic test in Asia to 
receive national government approval. Unlike most Western diagnostic tests have 
conducted their clinical trials in western countries, GenesWell BCT has been 
verified through multiple clinical trials targeting Asian patients. Gencurix 
plans to enter into the Japanese market based on these positive results.

www.gencurix.com/info@gencurix.com 

Source: Gencurix